Search Results
Your search for it matches 15756 pages
Showing 10601 - 10650Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer
Hypofractionated radiotherapy was not inferior to conventional radiotherapy in terms of disease-free survival among men with low-risk prostate cancer, according to the results of the phase III NRG Oncology RTOG 0415 trial reported in the Journal of Clinical Oncology by Lee et al. However, it was...
Cancer and Fertility Program Improves Patient Satisfaction With Information on Fertility Risks and Preservation
A cancer and fertility program established at Memorial Sloan Kettering Cancer Center (MSKCC) improves patient satisfaction with information received regarding fertility risks and preservation options, according to a report by Kelvin et al in the Journal of Clinical Oncology. Designed to support...
ELCC 2016: Osimertinib Given as First-Line Treatment May Alter Biology of EGFR-Mutated Non–Small Cell Lung Cancer
The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib (Tagrisso) is effective in the first-line treatment of EGFR-mutated non–small cell lung cancer (NSCLC), according to a late-breaking abstract presented by Ramalingam et al (Abstract...
ELCC 2016: Immunotherapy With Live Bacterium Improves Response Rate in Malignant Pleural Mesothelioma
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and a 59% response rate in patients with malignant pleural mesothelioma, according to the results of a phase Ib trial presented by Jahan et al April 14 (Abstract 208O_PR) at the European Lung...
The Parker Foundation Launches the Parker Institute for Cancer Immunotherapy With a $250 Million Grant
On April 13, The Parker Foundation announced a $250 million grant to launch the Parker Institute for Cancer Immunotherapy, a collaboration between scientists, clinicians, and industry partners to lead an unprecedented cancer immunotherapy research effort. The gift is the largest single contribution ...
Differences in Marital Status and Cancer Mortality by Race/Ethnicity and Nativity Explored
Previous studies have shown that married patients with cancer fare better than unmarried patients with cancer, surviving more often and longer. In a new study, published by Martínez et al in Cancer, researchers at University of California, San Diego, School of Medicine reported that the...
Preclinical Studies Show Many Androgen-Deprivation Therapies May Suppress Adaptive Immune Responses
Prostate cancer patients and their doctors may want to think twice about the best timing for chemotherapy or radiation therapy in conjunction with a common nonsurgical treatment, based on international research findings led by UT Southwestern Medical Center investigators. Researchers using mouse...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young people in the United States—and millions worldwide—from life-threatening cancers, ASCO said April 11 in a policy statement. Published by Bailey et al in the Journal of Clinical Oncology,...
Hormone Combination Therapy May Increase Risk of Breast Cancer in African American Women
The use of combination therapy with estrogen plus progestin, previously shown to be associated with an increased incidence of estrogen receptor–positive breast cancer in postmenopausal women in studies based largely on white women, has been shown to increase this type of breast cancer...
Shorter Delays Between Diagnosis, Surgery, and Chemotherapy Initiation May Improve Survival in Breast Cancer
The survival benefits of reducing the time to surgery following a diagnosis of breast cancer, and time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a...
Relatives of Patients With Carcinoma of Unknown Primary at Increased Risk for This and Other Cancers
Relatives of patients with carcinoma of unknown primary are at increased risk of developing it themselves as well as several other malignant neoplasms, including lung, pancreatic, and colon cancers; non-Hodgkin lymphoma; and myeloma, according to a study published in JAMA Oncology. “Some of...
In Early Brain Radiation Recovery Studies, Cranial Grafting of Stem Cell–Derived Therapy Improves Cognition and Reduces Neuropathology
While stem cells have shown promise for treating brain regions damaged by cancer radiation treatments, University of California, Irvine (UCI) researchers have found that microscopic vesicles isolated from these cells provide similar benefits without some of the risks associated with stem cells....
p53- and Mevalonate Pathway–Driven Cancers Require Cell-Signaling Protein Arf6 for Metastasis and Drug Resistance
A metabolic pathway that is upregulated in certain breast cancers promotes the disease's progression by activating a cell-signaling protein called Arf6, according to findings published by Hashimoto et al in the Journal of Cell Biology. The study, conducted by a team of researchers at Hokkaido...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists would disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast...
UK Trial Shows Similar Survival With PET-CT Surveillance vs Planned Neck Dissection in Advanced Head and Neck Cancer
In a UK noninferiority trial reported in The New England Journal of Medicine, Mehanna et al found that positron-emission tomography–computed tomography (PET-CT) surveillance was associated with similar survival vs planned neck dissection in patients with stage N2 or N3 squamous cell carcinoma ...
sFRP2 in Aged Melanoma Tumor Cells Drives Metastasis and Therapy Resistance
Cancer risk increases with one's age as accumulated damage to our cells and chronic inflammation occur over time. Now, an international team of scientists led by The Wistar Institute has shown that aged tumor cells in melanoma behave differently from younger tumor cells, according to study results...
Compartmentalizing Cancer
I was the last one on the oncology team to meet Mel. He was 36 years old, and by then Mel had been living with metastatic colon cancer for several years. During that time, his clinicians had never referred him to our psycho-oncology team because of his strong attitude and outlook. Mel’s outward...
Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older
A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was published in the Journal of Oncology Practice. The corresponding author...
10 Bladder Cancer Projects Awarded Research Grants by Johns Hopkins Greenberg Bladder Cancer Institute
The Johns Hopkins Greenberg Bladder Cancer Institute is a collaborative initiative of the Johns Hopkins Kimmel Cancer Center, the Brady Urological Institute, the Bloomberg School of Public Health, and the School of Medicine. It aims to develop new clinical strategies for combating bladder cancer...
AACR CEO Margaret Foti, PhD, MD (hc), Honored With James Ewing Layperson’s Award From SSO
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was recognized during the plenary session at the 69th Society of Surgical Oncology (SSO) Annual Cancer Symposium with the James Ewing Layperson’s Award for her dedication to the prevention and cure of cancer;...
A Political Activist Challenges the Drug Approval Process and the U.S. Government
The U.S. Food and Drug Administration’s (FDA’s) primary concern in the drug approval process is to ensure that the drug is safe and effective. For the past several decades, the advocacy groups have vociferously painted the agency as a stodgy bureaucracy that prevents desperate patients access to...
Things May Not Be What They Seem: Are Old Cancer Treatment Theories New Again?
The adage “you can’t judge a book by its cover,” is true, but authors still need to be aware of the importance of first impressions. The title of science writer Travis Christofferson’s book Tripping Over the Truth: The Return of the Metabolic Theory of Cancer Illuminates a New and Hopeful Path to ...
Crizotinib in ROS1-Positive Metastatic Non–Small Cell Lung Cancer
On March 11, 2016, crizotinib (Xalkori) was approved for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ROS1 rearrangement–positive tumors.1,2 A U.S. Food and Drug Administration–approved test for the detection of ROS1 rearrangements in NSCLC is not currently...
Lili Yang, PhD, Receives CIRM Funding to Investigate iNKT Modification and Transplantation
With new funding awarded by the California Institute for Regenerative Medicine (CIRM), Lili Yang, PhD, Assistant Professor in the Department of Microbiology, Immunology & Molecular Genetics and the Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research (BSCRC) at the...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Israel
The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Israel. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For...
Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer
The oncology research team at HonorHealth Research Institute in Scottsdale, Arizona, is spearheading a phase Ib/II trial that is demonstrating promising results with a novel regimen in patients with advanced pancreatic cancer. “The patients we are treating have advanced adenocarcinoma of the...
Susan Block, MD, Honored With AAHPM Palliative Care Lifetime Achievement Award
Susan Block, MD, an institute physician in the Department of Psychosocial Oncology and Palliative Care at Dana-Farber Cancer Institute, a Harvard Medical School Professor, and Director of the Serious Illness Care Program at Ariadne Labs, received the Lifetime Achievement Award at the American...
Samuel Waxman Cancer Research Foundation Appoints Robert Hromas, MD, to Its Scientific Advisory Board
The Samuel Waxman Cancer Research Foundation (SWCRF) announced the addition of cancer researcher Robert Hromas, MD, Chair of Medicine at University of Florida Health, to its scientific advisory board (SAB). Dr. Hromas, who continues his position at the University of Florida Health, will join his...
Providing Perspective on Pressing Economic Issues Facing Cancer Care—Now and in the Future
CANCERSCAPE, the 2016 Annual Meeting of the Association of Community Cancer Centers (ACCC), provided a forum for about 300 attendees to gain insight into the complexities of oncology treatment, where “clinical advances, policy mandates, and value-based payment reform intersect.” Of particular...
ASCO Pledges to Advance Interoperability Among Health Information Systems
ASCO has joined members of the health-care community in pledging to the U.S. Department of Health and Human Services (HHS) to commit to principles that will advance interoperability among health information systems. A formal announcement of the initiative was delivered by HHS Secretary Sylvia M....
Understanding and Preparing for MACRA
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed in April 2015, introducing comprehensive changes to how Medicare pays physicians for services. As the policies passed in MACRA are rolled out over the coming years, they will profoundly impact reimbursement and care...
Diversity Training Key to Increasing Cultural Competence Among Oncology Surgeons
A study in the Journal of Oncology Practice (JOP)1 measured the level of cultural competence among surgeons from six hospitals in the Puget Sound region of Washington State, home to a large population of American Indians and Alaskan Natives. According to the study, “Assessing Cultural Competence...
MicroRNA miR-181a Reduces NFκB Signaling in Diffuse Large B-Cell Lymphomas
A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in diffuse large B-cell lymphoma (DLBCL). By reducing NFκB...
Pathologic Complete Response to Neoadjuvant Therapy Associated With Improved Outcomes in HER2-Positive Breast Cancer
Pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer was associated with a significantly better outcome vs non–pathologic complete response, in a patient-level meta-analysis reported by Broglio et al in JAMA Oncology. Response vs No Response The study included...
New Commission on Cancer Standards Clarifies and Emphasizes Process, Quality, Data Reporting, and More
The 2016 edition of the Commission on Cancer’s accreditation standards manual clarifies and provides additional information in many areas and raises the bar for compliance in some, including psychosocial distress screening, survivorship care, data reporting, and activities in prevention and...
Outcome Measures in Quality and Identifying High-Quality Practice
At this year’s ASCO Quality Care Symposium, Craig Earle, MD, MSc, of the Ontario Institute for Cancer Research, used Donabedian’s Triad—structure, process, and outcome—to set the stage for his presentation on the science of quality. “The theory behind Donabedian’s Triad is that structure...
Experts Consider What It Means to Improve Quality of Care in an Era of Increasing Reliance on Targeted Therapies
Precision medicine is judged according to different values across the multiple stakeholders involved in cancer care. At this year’s Quality Care Symposium, presenters from different sectors of oncology addressed a central question: How do we assess quality in the age of precision medicine?1,2 Right ...
A Business Professor and Husband Turns Breast Cancer Researcher
In more than 25 years of viewing posters at oncology meetings, I’ve met researchers from virtually all professional walks of life, but it was not until the 2016 Miami Breast Cancer Conference, that the author’s affiliation turned my head: It was a business school. “Utilizing Metastatic Tumor...
Metastatic Breast Cancer With Discordant Tumors: Small Study Reports Treatment by Primary Status May Improve Survival
In a small retrospective series, patients with metastatic breast cancer treated according to the receptor status of the primary tumor, not the metastatic one, had significantly longer median overall survival. The study was reported at the 2016 Miami Breast Cancer Conference by T. Allen Pannell, Jr, ...
Breast Cancer Vaccines Moving Forward at a Fast Clip
Vaccines for both secondary and primary prevention of breast cancer are showing potential in clinical trials, according to Elizabeth A. Mittendorf, MD, PhD, who is leading much of the vaccine research at the University of Texas MD Anderson Cancer Center, Houston. Vaccine platforms being explored...
Expert Point of View: Kathleen Moore, MD
Session moderator Kathleen Moore, MD, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, Oklahoma City, said that while the response rates are “not incredibly high,” trabectedin offers another line of therapy where there previously was none. “I think ...
Trabectedin Improves Progression-Free Survival in Uterine Leiomyosarcoma
In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR] = 0.55, P < .001). According to the study’s authors, a lack of cumulative toxicity allows...
Computer-Assisted Decision Support in Medical Oncology: We Need It Now
Today’s medical oncologist is increasingly challenged to stay current with the latest developments in cancer treatment. I have been fortunate to speak with many oncologists over the past quarter-century on how professional life has evolved since the 1990s. These conversations have left me with a...
Throwing Out the Baby With the Bathwater: A Critical Appraisal of the USPSTF Recommendation Against Screening for Prostate Cancer
In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation against routine screening for prostate cancer.1,2 The grade D recommendation was considered controversial at the time, and remains so now, because many stakeholders have weighed the same body of evidence and come to...
The POPLAR Trial: PD-L1 Blockade With Atezolizumab in Second- or Third-Line Non–Small Cell Lung Cancer
The randomized phase II POPLAR trial—reported by Fehrenbacher and colleagues and reviewed in this issue of The ASCO Post—is another key piece of information for the medical community regarding the value of immune checkpoint blockers in second/third-line treatment of patients with non–small cell...
ENDO 2016: Engineered Ovary Implant Restores Fertility in Mice
Northwestern University scientists used a three-dimensional (3D) printer to create a prosthetic ovary—an implant that allowed mice that had their ovaries surgically removed to bear live young. The results were presented by Laronda et al on Saturday, April 2, at the Endocrine Society's Annual...
ENDO 2016: BPA Changes Fetal Development of the Mammary Gland, Can Raise Breast Cancer Risk
A new culture system that tests the role of chemical exposure on the developing mammary gland has found that bisphenol A (BPA) directly affects the mammary gland of mouse embryos. The study results, presented by Speroni et al Friday, April 1, at the Endocrine Society's Annual Meeting in Boston...
TP53 Gene Variant S47 May Contribute to Increased Cancer Risk in People of African Descent
For years, clinical data have shown that African Americans have a higher death rate and shorter period of survival among patients with commonly diagnosed cancers. While studies have focused on whether socioeconomic factors contribute to these statistics, researchers have been diligently trying to...
Widely Cited Prostate-Specific Antigen Screening Publications Influence Biopsy Rates and Associated Complications
While absolute rates of biopsy and postbiopsy complications have decreased following several benchmark prostate-specific antigen (PSA) screening publications, the relative risk for each patient continues to increase, according to a new study by Mayo Clinic researchers. The study is the largest to...
Lung Cancer Incidence and Mortality in Individuals With a Negative Low-Dose CT Prevalence Screen
In an analysis of the National Lung Screening Trial (NLST) cohort reported in The Lancet Oncology, Patz et al found that participants who had a negative low-dose computed tomography (CT) prevalence screen had a low incidence of lung cancer detected at first annual screen and exhibited reduced...
